MannKind Corporation (NASDAQ:MNKD) announced in a press release today that it will be giving presentations at three major conferences during the month of June. The company will be presenting at healthcare conferences sponsored by Jefferies, Goldman Sachs Group Inc (NYSE:GS) and Wells Fargo & Co. (NYSE:WFC).
MannKind plans presentations
According to the press release, Jefferies’ conference is the first one. The 2014 Global Healthcare Conference is scheduled for June 2 in New York City. MannKind Corporation (NASDAQ:MNKD) said its presentation is scheduled for 2:30 p.m. Eastern.
Goldman Sachs Group Inc (NYSE:GS)’s 35th Annual Global Healthcare Conference is scheduled for June 12. The conference will be held at the Terranea Resortin Rancho Palos Verdes in California. MannKind Corporation (NASDAQ:MNKD)’s presentation is scheduled for 11:20 a.m. Pacific.
Wells Fargo & Co. (NYSE:WFC) will hold its 2014 Healthcare Conference on June 17 at the InterContinental in Boston, Mass. MannKind Corporation (NASDAQ:MNKD) will present at 10 a.m. Eastern. All of the conferences will also be available via webcast on MannKind Corporation (NASDAQ:MNKD)’s website.
MannKind’s future hinges on Afrezza
MannKind Corporation (NASDAQ:MNKD)’s diabetes drug is currently under review by the U.S. Food and Drug Administration. Analysts have been becoming slightly more positive on the drug maker as it looks surer and surer that Afrezza will receive approval. Some believe sales of the Type 1 and Type 2 diabetes drug could reach $3.65 billion per year by 2025.
An advisory committee for the FDA delayed the Prescription Drug User Fee Act (PDUFA) review by three months, pushing the date back to July 15. That was initially seen as a negative, although at least one analyst believes MannKind Corporation (NASDAQ:MNKD) could get approval even before the new later date set by drug regulators.
MannKind Corporation (NASDAQ:MNKD) management is also reportedly in the final discussions with the FDA about REMS, labeling and the phase IV study being conducted in pediatric patients. Analysts generally see very little risk to Afrezza getting approved. The drug is the first in the company’s pipeline and so would be the only one it has in the market if the FDA approves it.
